# Tebipenem PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tebipenem

> The FDA approved tebipenem, sponsored by Spero Therapeutics, Inc. (SPRO), on June 17, 2026 for complicated urinary tract infections.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is tebipenem FDA approved?

Yes. The FDA approved tebipenem, sponsored by Spero Therapeutics, Inc. (SPRO), on June 17, 2026 for complicated urinary tract infections. SEC Form 10-Q: "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." [Calendar and source filings](https://sec-api.dev/pdufa/tebipenem)

Source: SEC Form 10-Q, accession 0001193125-26-458593, https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/tebipenem#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | tebipenem |
| Codes |  |
| Sponsor | Spero Therapeutics, Inc. (SPRO) https://sec-api.dev/companies/spro/catalysts |
| Indications | [complicated urinary tract infections](https://sec-api.dev/indications/complicated-urinary-tract-infections) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Jun 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0000950170-25-046125): "In June 2022, we received a Complete Response Letter ("CRL") from the FDA regarding our NDA." https://www.sec.gov/Archives/edgar/data/1701108/000095017025046125/spro-20241231.htm

### Dec 2022: NDA/BLA acceptance

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0000950170-25-046125): "We included data from our completed ADAPT-PO Phase 3 clinical trial of tebipenem HBr, together with requisite safety data, chemistry, manufacturing and controls ("CMC") information, clinical pharmacology and nonclinical studies, in our New Drug Application ("NDA") submission to the FDA, which was accepted by the FDA in late December 2022." https://www.sec.gov/Archives/edgar/data/1701108/000095017025046125/spro-20241231.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-03-27, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-118882): "This pre-specified interim analysis is expected in Q2 2025." https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-065633): "This pre-specified interim analysis is expected in Q2 2025." https://www.sec.gov/Archives/edgar/data/1701108/000119312525065633/d906623dex991.htm
- SEC Form 10-Q (accession 0000950170-25-070380): "As previously announced in March 2025, a pre-specified interim analysis of PIVOT-PO is expected to be completed in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1701108/000095017025070380/spro-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-118882): "Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025" https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-065633): "Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025" https://www.sec.gov/Archives/edgar/data/1701108/000119312525065633/d906623dex991.htm

### December 19, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: complicated urinary tract infections.
- First seen 2025-12-19, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-126244): "In December 2025, GSK resubmitted the tebipenem HBr NDA to the FDA." https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475dex991.htm
- SEC Form 8-K (accession 0001193125-25-325821): "On December 19, 2025, Spero Therapeutics, Inc. (the "Company") announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK"), filed a New Drug Application ("NDA") resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis." https://www.sec.gov/Archives/edgar/data/1701108/000119312525325821/d212013d8k.htm

### June 17, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: complicated urinary tract infections.
- First seen 2026-06-22, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001193125-26-458593): "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-458593): "On June 17, 2026, we and GSK announced that the FDA approved Utebzi (tebipenem pivoxil)." https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-346795): "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." https://www.sec.gov/Archives/edgar/data/1701108/000119312526346795/spro-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-346795): "On June 17, 2026, we and GSK announced that the FDA approved Utebzi (tebipenem pivoxil)." https://www.sec.gov/Archives/edgar/data/1701108/000119312526346795/spro-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-277506): "CAMBRIDGE, Mass., June 17, 2026 — Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisa, caused by certain susceptible pathogensb in adult patients who have limited or no alternative oral treatment options." https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-346855): "In June 2026, Spero and GSK announced that the U.S. Food and Drug Administration (FDA) approved Utebzi for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249dex991.htm
- SEC Form 10-Q (accession 0001193125-26-458593): "On June 17, 2026, the Company and GSK announced that the FDA approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-458593): "On June 17, 2026, we and GSK announced that the FDA approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-346795): "On June 17, 2026, the Company and GSK announced that the FDA approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." https://www.sec.gov/Archives/edgar/data/1701108/000119312526346795/spro-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-346795): "On June 17, 2026, we and GSK announced that the FDA approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." https://www.sec.gov/Archives/edgar/data/1701108/000119312526346795/spro-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-346795): "In June 2026, the U.S. Food and Drug Administration ("FDA") approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil), and we have since shifted our focus and resources to advancing the development of SP001." https://www.sec.gov/Archives/edgar/data/1701108/000119312526346795/spro-20260630.htm

### June 18, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-03-26, last confirmed 2026-05-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-221567): "New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026" https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-221567): "Act (PDUFA) date to complete the review of the tebipenem HBr NDA as June 18, 2026." https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-126244): "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the anticipated PDUFA date set by the FDA as June 18, 2026; Spero's exploration of opportunities to expand its portfolio of clinical stage product candidates; the potential of tebipenem HBr to be the first oral carbapenem antibiotic for US patients with cUTI, including pyelonephritis, and to set a new standard of care; the potential receipt of milestone payments under Spero's license and collaboration agreements;" https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-221567): "the anticipated PDUFA date set by the FDA as June 18, 2026" https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm
- SEC Form 10-K (accession 0001193125-26-126192): "The NDA was accepted by the FDA, and GSK reported that the PDUFA date has been set as June 18, 2026." https://www.sec.gov/Archives/edgar/data/1701108/000119312526126192/spro-20251231.htm
- SEC Form 10-Q (accession 0001193125-26-458593): "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tebipenem.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tebipenem PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tebipenem

```bibtex
@misc{secapidev_pdufa_tebipenem_20261116,
  title        = {Tebipenem PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tebipenem}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tebipenem_20261116","title":"Tebipenem PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tebipenem","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
